# OnCo record step-up-dosing (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/step-up-dosing/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "step-up-dosing" ;
  schema:name "Step-up dosing (T-cell engagers)"@en ;
  schema:alternateName "step-up"@en, "step-up dose"@en, "step-up doses"@en, "priming dose"@en, "ramp-up"@en, "ramp-up dosing"@en, "venetoclax ramp-up"@en, "dose ramp"@en, "inpatient monitoring"@en, "outpatient administration"@en, "outpatient step-up"@en ;
  schema:description "Starting a bispecific T-cell engager (teclistamab, glofitamab, epcoritamab, tarlatamab) at a tiny dose and increasing it over the first week, so T cells are switched on gradually and the fever-and-low-blood-pressure reaction (cytokine release syndrome) stays mild. The hospital stay it needs has slowed community adoption."@en ;
  schema:url <https://onco.cc/terms/step-up-dosing/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Bispecific_T-cell_engager> ;
  schema:citation <https://en.wikipedia.org/wiki/Bispecific_T-cell_engager> ;
  onco:related <https://onco.cc/terms/crs/>, <https://onco.cc/terms/icans/>, <https://onco.cc/technologies/community-oncology-networks/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:drugs <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/tarlatamab/>, <https://onco.cc/drugs/venetoclax/> .